300016 Stock Overview
Researches, develops, produces, and sells pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Beijing Beilu Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.85 |
| 52 Week High | CN¥8.97 |
| 52 Week Low | CN¥3.58 |
| Beta | 0.43 |
| 11 Month Change | -14.80% |
| 3 Month Change | 41.53% |
| 1 Year Change | -10.69% |
| 33 Year Change | -14.91% |
| 5 Year Change | -16.26% |
| Change since IPO | 29.88% |
Recent News & Updates
Shareholder Returns
| 300016 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.7% | -1.4% | -2.0% |
| 1Y | -10.7% | -6.0% | 4.6% |
Return vs Industry: 300016 underperformed the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 300016 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
| 300016 volatility | |
|---|---|
| 300016 Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300016 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300016's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 952 | Xu Wang | www.beilu.com.cn |
Beijing Beilu Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd.
Beijing Beilu Pharmaceutical Co., Ltd Fundamentals Summary
| 300016 fundamental statistics | |
|---|---|
| Market cap | CN¥3.37b |
| Earnings (TTM) | -CN¥49.30m |
| Revenue (TTM) | CN¥970.62m |
3.5x
P/S Ratio-68.3x
P/E RatioIs 300016 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300016 income statement (TTM) | |
|---|---|
| Revenue | CN¥970.62m |
| Cost of Revenue | CN¥549.91m |
| Gross Profit | CN¥420.71m |
| Other Expenses | CN¥470.01m |
| Earnings | -CN¥49.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 43.34% |
| Net Profit Margin | -5.08% |
| Debt/Equity Ratio | 46.6% |
How did 300016 perform over the long term?
See historical performance and comparison